Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation, Sintilimab, and Lenvatinib in Advanced Biliary Tract Cancer
NCT05781074Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab and lenvatinib in biliary tract cancer (BTC), sponsored by Fudan University. Started Mar 2023; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05781074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781074.